Immunovant's total assets for Q4 2025 were $776.22M, an increase of 84.41% from the previous quarter. IMVT total liabilities were $68.78M for the fiscal quarter, a 0.67% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.